BioXcel Therapeutics Inc (FRA:BX2)
€ 1.892 0.006 (0.32%) Market Cap: 72.49 Mil Enterprise Value: 98.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 21/100

BioXcel Therapeutics Inc at Barclays Global Healthcare Conference Transcript

Mar 15, 2022 / 07:50PM GMT
Release Date Price: €15.81
Justin Hayward Burns
Barclays Bank PLC, Research Division - Research Analyst

All right. Good afternoon, everyone. Thanks for joining us at the 2022 Barclays Global Healthcare Conference. My name is Justin Burns. I'm an associate on the U.S. Biopharmaceuticals team, and it's my pleasure to introduce Dr. Vimal Mehta and BioXcel Therapeutics.

Vimal D. Mehta
BioXcel Therapeutics, Inc. - Founder, CEO, President, & Director

Thank you, Justin. Thank you to our hosts at Barclays for the opportunity to present today, and good afternoon to all of you.

I will be making some forward-looking statements, and my goal today will be to introduce the company as well as provide you update that -- exciting things that are happening around our business for 2022.

So as you know, BioXcel Therapeutics is developing transformative medicines using AI-based approach, artificial intelligence-based approaches in neuroscience and immuno-oncology. Our lead products are -- 2 lead products are BXCL501 and BXCL701. 501 is investigational proprietary orally dissolving

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot